{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:13:25Z","timestamp":1773015205838,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["trasci.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.transci.2024.104040","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T03:57:30Z","timestamp":1732939050000},"page":"104040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparing cryoprecipitate-poor plasma to fresh frozen plasma as replacement therapy in thrombotic thrombocytopenic purpura: An updated meta-analysis"],"prefix":"10.1016","volume":"64","author":[{"given":"Marcela","family":"Mafra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Meritxell Roca","family":"Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Everton","family":"Castanha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Godoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Valenzuela S","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"44","key":"10.1016\/j.transci.2024.104040_bib1","doi-asserted-by":"crossref","first-page":"41059","DOI":"10.1074\/jbc.C100515200","article-title":"Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura","volume":"276","author":"Zheng","year":"2001","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.transci.2024.104040_bib2","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"130","author":"Sadler","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.transci.2024.104040_bib3","first-page":"1653","article-title":"Hereditary Thrombotic Thrombocytopenic Purpura","volume":"381","author":"Kremer Hovinga","year":"2019"},{"issue":"21","key":"10.1016\/j.transci.2024.104040_bib4","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.transci.2024.104040_bib5","doi-asserted-by":"crossref","unstructured":"George J.N.. Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2006;","DOI":"10.1056\/NEJMcp053024"},{"issue":"10","key":"10.1016\/j.transci.2024.104040_bib6","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.transci.2024.104040_bib7","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1016\/j.transci.2024.104040_bib8","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1111\/trf.12182","article-title":"ADAMTS13 unbound to larger von Willebrand factor multimers in cryosupernatant: implications for selection of plasma preparations for thrombotic thrombocytopenic purpura treatment","volume":"53","author":"Hori","year":"2013","journal-title":"Transfus (Paris)"},{"issue":"5","key":"10.1016\/j.transci.2024.104040_bib9","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.V65.5.1232.1232","article-title":"Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura","volume":"65","author":"Moake","year":"1985","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.transci.2024.104040_bib10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.ajkd.2008.07.038","article-title":"Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials","volume":"53","author":"Michael","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.transci.2024.104040_bib11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jca.21336","article-title":"Safety and efficacy of cryoprecipitate\u2010poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: a single center retrospective evaluation","volume":"29","author":"Stefanello","year":"2014","journal-title":"J Clin Apher"},{"issue":"1","key":"10.1016\/j.transci.2024.104040_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.transci.2006.05.014","article-title":"Therapeutic plasma exchange for the treatment of thrombotic thrombocytopenic purpura: a retrospective multicenter study","volume":"36","author":"Altuntas","year":"2007","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2024.104040_bib13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"Mar 29","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.transci.2024.104040_bib14","unstructured":"Higgins J., Thomas J., Chandler J., Cumpston M., Li T., Page M., et al., editors. Cochrane Handbook for Systematic Reviews of interventions version 6.4 (updated August 2023) [Internet]. Cochrane; 2023. Available from: \u3008www.training.cochrane.org\/handbook\u3009."},{"issue":"6","key":"10.1016\/j.transci.2024.104040_bib15","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"10.1016\/j.transci.2024.104040_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Method"},{"issue":"2","key":"10.1016\/j.transci.2024.104040_bib17","first-page":"192","article-title":"Interpretation of subgroup analyses in systematic reviews: A tutorial. Clin Epidemiol","volume":"7","author":"Richardson","year":"2019","journal-title":"Glob Health"},{"key":"10.1016\/j.transci.2024.104040_bib18","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.transci.2024.104040_bib19","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.transci.2024.104040_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2141.2005.05418.x","article-title":"Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet","volume":"129","author":"Rock","year":"2005","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.transci.2024.104040_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1526-0968.2000.004005327.x","article-title":"For the prodromi study group LCR. Design of the prospective randomized study for the treatment of patients with thrombotic microangiopathy","volume":"4","author":"R\u00f6thele","year":"2000","journal-title":"Ther Apher"},{"issue":"1","key":"10.1016\/j.transci.2024.104040_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jca.1003","article-title":"Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP)","volume":"16","author":"Zeigler","year":"2001","journal-title":"J Clin Apher"},{"issue":"2","key":"10.1016\/j.transci.2024.104040_bib23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1365-2141.1996.d01-1800.x","article-title":"And the members of the canadian apheresis group. cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura","volume":"94","author":"Rock","year":"1996","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.transci.2024.104040_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/jca.1025","article-title":"Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura","volume":"16","author":"Reutter","year":"2001","journal-title":"J Clin Apher"},{"issue":"4","key":"10.1016\/j.transci.2024.104040_bib25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/jca.2920100404","article-title":"Influence of type of exchange fluid on survival in therapeutic apheresis for thrombotic thrombocytopenic purpura","volume":"10","author":"Owens","year":"1995","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2024.104040_bib26","series-title":"Cochrane handbook for systematic reviews of interventions version 64 (updated August 2023) [Internet]. Cochrane","article-title":"Chapter 13: Assessing risk of bias due to missing results in a synthesis","author":"Page","year":"2023"},{"issue":"6","key":"10.1016\/j.transci.2024.104040_bib27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.transci.2024.104040_bib28","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/labmed\/lmab092","article-title":"Is Cryoprecipitate-reduced plasma an efficacious replacement fluid for therapeutic plasma exchange for patients with thrombotic microangiopathy? A single-center retrospective experience","volume":"53","author":"Kim","year":"2022","journal-title":"Lab Med"},{"issue":"3","key":"10.1016\/j.transci.2024.104040_bib29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jca.21352","article-title":"Outcomes of plasma exchange in patients with transplant\u2010associated thrombotic microangiopathy based on time of presentation since transplant","volume":"30","author":"Mulay","year":"2015","journal-title":"J Clin Apher"},{"issue":"1","key":"10.1016\/j.transci.2024.104040_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-3148.2006.00720.x","article-title":"A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura","volume":"17","author":"Brunskill","year":"2007","journal-title":"Transfus Med"},{"key":"10.1016\/j.transci.2024.104040_bib31","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor\u2013cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic\u2013uremic syndrome","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.transci.2024.104040_bib32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1537-2995.2007.01074.x","article-title":"Comparison and stability of ADAMTS13 activity in therapeutic plasma products","volume":"47","author":"Scott","year":"2007","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.transci.2024.104040_bib33","article-title":"Thrombotic microangiopathies: an illustrated review","volume":"6","author":"Abou\u2010Ismail","year":"2022","journal-title":"Res Pr Thromb Haemost"},{"issue":"6","key":"10.1016\/j.transci.2024.104040_bib34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.transci.2024.104040_bib35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.transci.2024.104040_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/jth.15194","article-title":"Should all patients with immune\u2010mediated thrombotic thrombocytopenic purpura receive caplacizumab?","volume":"19","author":"Picod","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.transci.2024.104040_bib37","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1080\/13696998.2021.1992413","article-title":"Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective","volume":"24","author":"Pollissard","year":"2021","journal-title":"J Med Econ"},{"issue":"7","key":"10.1016\/j.transci.2024.104040_bib38","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood.2020006052","article-title":"Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"137","author":"Goshua","year":"2021","journal-title":"Blood"},{"issue":"03","key":"10.1016\/j.transci.2024.104040_bib39","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1055\/a-1171-0473","article-title":"Current and future perspectives on ADAMTS13 and thrombotic thrombocytopenic purpura","volume":"40","author":"Roose","year":"2020","journal-title":"H\u00e4mostaseologie"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050224002210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050224002210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T08:48:18Z","timestamp":1738572498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050224002210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1473050224002210"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2024.104040","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing cryoprecipitate-poor plasma to fresh frozen plasma as replacement therapy in thrombotic thrombocytopenic purpura: An updated meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2024.104040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104040"}}